Barclays Maintains an 'Overweight' on Celgene (CELG); Stumble in Europe, But Expect Continued U.S. Growth

June 22, 2012 2:56 PM EDT Send to a Friend
Get Alerts CELG Hot Sheet
Price: $92.26 -0.33%

Rating Summary:
    22 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 14 | New: 38
Trade CELG Now!
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Celgene (NASDAQ: CELG) price target of $74.00 (from $83.00).

Analyst, Ying Huang, said, "Withdrawal of European application is disappointing, yet not completely unexpected...We lower our PT to $74, but stock should be supported by floor valuation of $60. Even without front-line maintenance approval in Europe, Revlimid should continue to grow in both the US and Europe on longer duration and higher number of patients."

Barclays lowers FY13 EPS estimate from $5.27 to $4.86.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $59.45 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities


Add Your Comment